Skip to main content
OpenTrials
Completed

NCT Number: NCT03319693

Molecular Characterization of Primary Mucosal Melanoma

Primary mucosal melanomas (MPM) are rarer than cutaneous melanomas, but also more severe. They are usually refractory to conventional approaches, regularly excluded from major therapeutic programs and not sensitive to new targeted therapies orphans. " The identification of therapeutic targets and accessibility to existing, developing or future targeted therapies improves the survival of patients with MPM.

The principal goal is to describe, using a large panel of genes, the prevalence of major mutations in a cohort of MPMs based on the population of a French region.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Chu Reims

Reims, 51092, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Incident Mucosal melanoma in the Champagne-Ardenne region 2004-2014

Exclusion criteria

  • Cutaneous melanoma
  • Uveal melanoma

Treatment and study plan

Somatic Genetic

Genetic

NGS analysis

Primary outcomes

  1. The frequency of main mutations identified using the NGS panel

    Time frame: Day 0

    NGS panel

Sponsors and collaborators

Lead sponsor

CHU de Reims

Other

Registry information

Acronym: MELMUQ

Important dates

Study start
2017
Primary completion
2019
Study completion
2021
First posted
Oct 24, 2017
Registry last updated
Aug 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.